OMC-Kenner is one of about 100 sites in the country to offer PRRT and is the only site in Louisiana..
NEW ORLEANS — To meet the growing demand from patients across the country, Ochsner Medical Center- Kenner (OMC-Kenner) opened a new, dedicated infusion space to administer the recently FDA-approved Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors (NETs). OMC-Kenner is one of about 100 sites in the country to offer PRRT and is the only site in Louisiana.
A NET is a rare, hormone-producing tumor that affects neuroendocrine cells, which are present throughout the nervous and endocrine systems. NETs can originate anywhere in the body. Carcinoid tumors, however, are the most common kind detected and are usually found in the lungs or GI tract. Most of the time it grows very slowly and because it is so often difficult to detect, diagnosis is delayed on average of 10 years. Approximately 12,000 people in the United States are diagnosed with a neuroendocrine tumor every year.
“NET diagnoses have tripled in the last decade alone, so there is a huge and unmet need. Treatment is multi-disciplinary, with local and systemic forms of therapies available. With new agents on the horizon, the challenge now becomes to shrink the disease, while continuing to improve the quality of life,” said Robert Ramirez, DO, FACP, medical oncologist, OMC-Kenner.
OMC-Kenner is home to the Neuroendocrine Program, which specializes in the diagnosis and management of all forms of neuroendocrine tumors. It has been a national leader for more than a decade in the treatment and management of this condition. The Neuroendocrine Program at OMC-Kenner is witnessing more people living beyond 10 years. This can be attributed to advancements in clinical trials, surgical and non-surgical procedures and medical management.
To read the full press release click here.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
QCCA, NCCA Merge to Form ONCare Among Independent Oncology Practices
February 29th 2024ONCare Alliance will be led by 2 of the leading women in community oncology, cochairs Barbara McAneny, MD, of the New Mexico Cancer Center, and Sibel Blau, MD, of Northwest Medical Specialties, PLLC, of Puyallup, Washington.
Read More